Table 1.
Blood | Distribution | |||||||
---|---|---|---|---|---|---|---|---|
Group | Treatment | Cohort | n | No. positive | Range of positivity (copies/μg) | Low | Medium | High |
1 | B6C3F1 Control | 30 | 15 | 0 | 0–0 | 0 | 0 | 0 |
90 | 15 | 0 | 0–0 | 0 | 0 | 0 | ||
120 | 15 | 0 | 0–0 | 0 | 0 | 0 | ||
150 | 15 | 0 | 0–0 | 0 | 0 | 0 | ||
180 | 5 | 0 | 0–0 | 0 | 0 | 0 | ||
2 | B6C3F1 Toca 511 107 IV | 30 | 20 | 20 | 2,030–49,779 | 9 | 11 | 0 |
90 | 20 | 20 | 167–23,096 | 18 | 2 | 0 | ||
120 | 19 | 18 | 576–9,753 | 18 | 0 | 0 | ||
150 | 19 | 18 | 259–11,459 | 18 | 0 | 0 | ||
180 | 20 | 20 | 199–14,823 | 20 | 0 | 0 |
IV, intravenous.